|
【结 构 式】 
|
【分子编号】54368 【品名】5-methyl-1-{[2-(trimethylsilyl)ethoxy]methyl}-2,4(1H,3H)-pyrimidinedione 【CA登记号】 |
【 分 子 式 】C11H20N2O3Si 【 分 子 量 】256.37698 【元素组成】C 51.53% H 7.86% N 10.93% O 18.72% Si 10.95% |
与该中间体有关的原料药合成路线共 1 条
合成路线1
该中间体在本合成路线中的序号：(IX)5-Methyluracil (VII) was protected with SEM-Cl (VIII) to yield the 1-SEM derivative (IX), which was subsequently alkylated with 1-bromo-3-chloropropane (X) under phase-transfer conditions to provide chloride (XI). Alkylation of piperazine (VI) with chloride (XI) in the presence of NaI and K2CO3 furnished adduct (XII). The title compound was then obtained by deprotection of (XII) upon treatment with tetrabutylammonium fluoride in THF.
| 【1】 Bantle, G.W.; Elworthy, T.R.; Guzman, A.; Jaime-Figueroa, S.; Lopez-Tapia, F.J.; Morgans, D.J. Jr.; Perez-Medrano, A.; Pfister, J.R.; Sjogren, E.B.; Talamas, F.X. (F. Hoffmann-La Roche AG); Pyrimidinedione, pyrimidinetrione, triazinedione, tetrahydroquinazolinedione derivs. as alpha1-adrenergic receptor antagonists. EP 0748800; JP 1997100269 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (VI) | 54367 | 1-[4-fluoro-2-(2,2,2-trifluoroethoxy)phenyl]piperazine; 5-fluoro-2-(1-piperazinyl)phenyl 2,2,2-trifluoroethyl ether | C12H14F4N2O | 详情 | 详情 | |
| (VII) | 12204 | 5-Methyl-2,4(1H,3H)-pyrimidinedione; Thymine | 65-71-4 | C5H6N2O2 | 详情 | 详情 |
| (VIII) | 27243 | [2-(chloromethoxy)ethyl](trimethyl)silane | 76513-69-4 | C6H15ClOSi | 详情 | 详情 |
| (IX) | 54368 | 5-methyl-1-{[2-(trimethylsilyl)ethoxy]methyl}-2,4(1H,3H)-pyrimidinedione | C11H20N2O3Si | 详情 | 详情 | |
| (X) | 10358 | 1-Bromo-3-chloropropane | 109-70-6 | C3H6BrCl | 详情 | 详情 |
| (XI) | 54369 | 3-(3-chloropropyl)-5-methyl-1-{[2-(trimethylsilyl)ethoxy]methyl}-2,4(1H,3H)-pyrimidinedione | C14H25ClN2O3Si | 详情 | 详情 | |
| (XII) | 54370 | 3-(3-{4-[4-fluoro-2-(2,2,2-trifluoroethoxy)phenyl]-1-piperazinyl}propyl)-5-methyl-1-{[2-(trimethylsilyl)ethoxy]methyl}-2,4(1H,3H)-pyrimidinedione | C26H38F4N4O4Si | 详情 | 详情 |
Extended Information